Clinical trials: Major Cardiovascular Event
Ischemia, Cardiac Death
A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions
E.V.O.L.U.T.I.O.N.: A Randomized Study to Evaluate Safety and Efficacy of the Excel Sirolimus Eluting Stent with a Biodegradable Polymer Versus Sirolimus Eluting Stent with a Non-Biodegradable Polymer in the Treatment of Patients…
- Conditions
- Ischemia, Cardiac Death, Myocardial Infarction
- Trial name
- EVOLUTION (NCT00825773)
- Testing
- Percutaneous Transluminal Coronary Angioplasty
- Where
- China
- Volunteers
- 1,944 people
- Sponsor
- JW Medical Systems Ltd
Coronary Artery Disease
The DANish COronary DEcalcification (DANCODE) Trial
1. Abstract Introduction Coronary artery calcification (CAC) and especially progression in CAC is a strong predictor of acute myocardial infarction and cardiovascular mortality.
- Trial name
- DANCODE (NCT05500443)
- Testing
- Vitamin K2 (Menaquinone-7)
- Where
- 3 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Odense University Hospital
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
ST Elevation Myocardial Infarction
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage.
- Trial name
- NCT03740776
- Volunteers
- 2 people
- Sponsor
- Dongying Zhang
Coronary Disease
Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)
This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after…
- Trial name
- (CAPP) (NCT01431495)
- Testing
- Pidogrel, Plavix
- Where
- Tunisia
- Volunteers
- 219 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Coronary Artery Disease, DES
A Randomized Comparison of CLOpidogrel Monotherapy Versus Extended Dual-antiplatelet Therapy Beyond 12 Months After Implantation of Drug-eluting StEnts in High-risk Lesions or Patients; A-CLOSE Trial
We hypothesized that clopidogrel mono-therapy will not be inferior to the extended DAPT in terms of the occurrence of both ischemic and bleeding events, for lesions or patients at high risk for either ischemic or bleeding…
- Trial name
- NCT03947229
- Testing
- Clopidogrel mono-therapy, Dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,200 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Plaque
PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT Study
This prospective cohort study aims to determine whether high-risk coronary plaques identified by novel Photon-Counting Detector CT (PCCT) independently predict future major adverse cardiovascular events (MACE).
- Conditions
- Coronary Artery Disease, Plaque, Photon-Counting Computed Tomography
- Trial name
- PREDICT (NCT07822737)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Chao Yang Hospital
Physical Activity, Coronary Artery Disease
Prognostic Impact of Physical Activity Patterns After Percutaneous Coronary Intervention (PIPAP Study)
Physical activity monitoring after coronary bypass grafting and other major surgeries has been found to be predictive for hospital readmission and adverse outcome.
- Trial name
- PIPAP (NCT04663373)
- Testing
- Step counting
- Where
- Switzerland
- Volunteers
- 568 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Obesity
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).
- Trial name
- INFORMUS (NCT06098079)
- Testing
- Naltrexone-Bupropion (NB) Combination
- Where
- 140 sites in United States
- Volunteers
- 8,600 people
- Sponsor
- Currax Pharmaceuticals
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Artificial Intelligence (AI), Hepatocellular Carcinoma (HCC)
Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients
This is an observational, low risk tissue based, non-pharmacological, retrospective-prospective study for adults heart and liver transplant patients, related to IRCCS Azienda Ospedaliero-Universitaria di Bologna (IRCCS AOUBO).
- Conditions
- Artificial Intelligence (AI), Hepatocellular Carcinoma (HCC), Heart Transplantation, Liver Transplantation
- Trial name
- DARE (NCT06774768)
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Coronary Artery Disease, In-stent Restenosis
CT-FFR-guided Strategy for In-stent Restenosis
This study will be a prospective, randomized clinical trial to compare standard practice guided by usual care testing to CT-FFR-guided management in patients with in-stent restenosis.
- Trial name
- NCT05611190
- Testing
- CT-FFR, Usual Care
- Volunteers
- 294 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Cardiovascular Diseases
SEDentary Lifestyle, Mortality and Major Adverse Clinical Outcomes in Chronic KIDney Disease
The goal of this study is to learn if a simple home exercise program can benefit patients with advanced chronic kidney disease. There is also an observational part of the study without an exercise program.
- Conditions
- Chronic Kidney Disease, Cardiovascular Diseases, Frailty
- Trial name
- SEDKID (NCT06935786)
- Testing
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- Where
- 3 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Turku University Hospital
Severe Aortic Valve Stenosis
Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation
The POPular ATLANTIS trial aims to investigate CT-guided antithrombotic therapy compared to lifelong single antiplatelet therapy after a transcatheter aortic valve implantation (TAVI) procedure.
- Trial name
- POP ATLANTIS (NCT06168370)
- Testing
- CT guided strategy
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- St. Antonius Hospital